SCHEMBL5545489

SCHEMBL5545489

CCOC(=O)CC(=O)N(CCN1C(=O)c2ccccc2C1=O)c1cc(Cc2ccc(F)cc2)cnc1C(=O)OCC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.41
KMT2A Q03164 4/20 0.41
NPSR1 Q6W5P4 3/20 0.41
MEN1 O00255 3/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
ALOX12 P18054 1/20 0.41
CCR6 P51684 1/20 0.41
HKDC1 Q2TB90 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
HTT P42858 2/20 0.40
TP53 P04637 1/20 0.40
PAX8 Q06710 1/20 0.40
TSHR P16473 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
POLB P06746 2/20 0.36
CYP2C19 P33261 3/20 0.36
CYP1A2 P05177 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539039 0.95 ALDH1A1 (0.40) ALDH1A1KMT2ANPSR1MEN1MAPT
SCHEMBL5545354 0.83 EPHX2 (0.42) ALDH1A1KMT2AMEN1MAPTCYP3A4
SCHEMBL5540997 0.81 PDE3B (0.35) ALDH1A1KMT2AMEN1LMNATP53
SCHEMBL5540690 0.81 MAOB (0.35) ALDH1A1KMT2ANPSR1MEN1MAPT
SCHEMBL5540995 0.80 PDE3B (0.35) ALDH1A1KMT2AMEN1LMNATSHR
SCHEMBL5541250 0.80 GRM2 (0.35) ALDH1A1KMT2AMEN1TSHRSMN1; SMN2
SCHEMBL5538835 0.80 PDE3B (0.38) ALDH1A1KMT2AMEN1MAPTTSHR
SCHEMBL5538668 0.80 PDE3B (0.40) ALDH1A1MAPTKDM4ETSHRSMN1; SMN2
SCHEMBL5547377 0.80 KDM4E (0.38) ALDH1A1KMT2ANPSR1MEN1MAPT
SCHEMBL5546803 0.80 MAPT (0.35) ALDH1A1KMT2ANPSR1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed
EP-1720856-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-15 EP disclosed
WO-2005077050-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 ALDH1A1 3812/4885KMT2A 502/4885NPSR1 4539/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 ALDH1A1 3073/4885KMT2A 819/4885NPSR1 4734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.